RxDoctor Payments Data

Arachchige Muthukuda, MD

Child & Adolescent Psychiatry · Baltimore, MDNPI 1073770616

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $485 of the $585 with a category attached, or 82.9%. It is spread thinly across 8 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $531, more than ten times the $32 reported in 2023.

$585in general payments, 2019–2025

Across 20 payments — averaging $29.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$126
  • Teva Pharmaceuticals USA, Inc.$120
  • Johnson & Johnson$84
  • Vanda Pharmaceuticals Inc.$74
  • E.r. Squibb & Sons, L.L.C.$65
  • Axsome Therapeutics, Inc.$54
  • plus $62 from 2 others

What the payments were for

  • Food & beverage$48583%
  • Education$10017%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$585 in reported general payments places this provider in the 70th percentile of 98 child & adolescent psychiatry providers in Maryland.

See all child & adolescent psychiatry providers in Maryland

Medicare billing

Part B allowed, 2024
$30,146
Medicare patients
61
Services billed
238

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole31$44,198
Lurasidone Hcl66$29,132
VraylarCariprazine Hcl16$23,094
FanaptIloperidone12$20,397
Bupropion XlBupropion Hcl87$7,260
Quetiapine Fumarate122$2,588
Fluoxetine Hcl80$1,983
Hydroxyzine Hcl77$1,886
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine36$1,789
Alprazolam106$1,599
Clozapine36$1,408
Aripiprazole34$1,285
Buspirone Hcl112$1,211
Risperidone132$1,188
Divalproex Sodium ErDivalproex Sodium17$1,076

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Vanda Pharmaceuticals Inc.Fanapt$74$20,39712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 98 child & adolescent psychiatry providers in Maryland.

Other child & adolescent psychiatry in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →